IL-12 P40 Monomer, Monoclonal Antibody Against P40 Homodimer and the Combination of the Two for Autoimmune Disease Treatment
Inactive Publication Date: 2014-10-23
RUSH UNIV MEDICAL CENT
View PDF2 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The patent text discusses the results of testing a combination of recombinant p40 and mAb-p402 on the disease process of EAE, a mouse model for MS. The results showed that recombinant p40 was able to improve the clinical symptoms and disease progression of EAE, while mAb-p402 was able to protect mice from EAE. Interestingly, when a combination of recombinant p40 and mAb-p402 was used, it was able to strongly inhibit the clinical symptoms of EAE. These results suggest that this combination treatment option could potentially be used as a new treatment option for patients with MS.
Problems solved by technology
Despite intense investigations, no effective therapy is available to stop its onset or halt its progression.
Despite extensive research to develop pharmacotherapeutic agents to ameliorate exacerbations and to reduce the number of exacerbations and subsequent progression of neurologic disability in MS, only a few therapies are available, which are not very efficient.
There is also a lack of effective therapies for other autoimmune diseases such as systemic lupus erythematosus (lupus), thyrioditis, rheumatoid arthritis, Sjogren's syndrome, Addison's disease etc., as well.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0027]While the example below is directed towards MS, this disclosure applies to other autoimmune diseases such as systemic lupus erythematosus (lupus), thyrioditis, rheumatoid arthritis, Sjogren's syndrome, Addison's disease etc., as well.
[0028]Experimental allergic encephalomyelitis (EAE) is an experimentally induced autoimmune disease of the CNS, and serves as an animal model for MS. When the effect of recombinant p402 and p40 and neutralizing mAbs against p402 and p40 in EAE was tested, the following was observed.
[0029]IL-12 p40 monomer prevents MS-like autoimmune demyelination in mice
[0030]IL-12 and IL-23 are known to aggravate the disease process of EAE. To understand the role of p40 monomer in the disease process of EAE, first, the level of p40 in the spleen (the most important immune organ) of EAE mice was monitored at different phases of the disease. Surprisingly, the level of p40 was significantly lower in spleen of EAE mice at the acute phase compared with control (FIG. 1...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| Permeability | aaaaa | aaaaa |
Login to View More
Abstract
A novel approach to discover new drugs against MS and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (IL-12), the p40 monomer (p40), the p40 homodimer (p402), and the IL-23. To facilitate the studies on p402 and p40, neutralizing monoclonal antibodies (mAb) against mouse p402 and p40 were generated for the first time. MS and other autoimmune disease drug therapies including recombinant p40 and / or monoclonal antibody against p402 (mAb-p402 a3-1d) are disclosed.
Description
BACKGROUND[0001]1. Technical Field:[0002]This disclosure relates to new drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (lupus), thyrioditis, rheumatoid arthritis, Sjogren's syndrome, Addison's disease etc.[0003]2. Description of the Related Art:[0004]Multiple sclerosis (MS) is the most common human demyelinating disease of the central nervous system (CNS). Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. MS is one of many autoimmune diseases and is a chronic human demyelinating disorder of the CNS of unknown etiology. From a clinical standpoint, MS is characterized by recurrent attacks of neurologic dysfunction. Pathologically, it can be identified by the presence of diffuse, discrete demyelinated areas, called plaques. MS is now widely viewed as an autoimmune disease that develops early in life (between the young ages of 20 and 40), perhaps after an unknown infe...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K39/395A61K38/20
CPCA61K38/208A61K39/3955C07K16/24A61P37/00A61K2300/00
Inventor PAHAN, KALIPADA
Owner RUSH UNIV MEDICAL CENT